Edition:
United States

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

2.12USD
16 Jul 2018
Change (% chg)

$0.02 (+0.95%)
Prev Close
$2.10
Open
$2.09
Day's High
$2.24
Day's Low
$2.09
Volume
6,721
Avg. Vol
16,581
52-wk High
$11.90
52-wk Low
$1.71

Chart for

About

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal... (more)

Overall

Beta: -7.54
Market Cap(Mil.): $32.04
Shares Outstanding(Mil.): 0.15
Dividend: --
Yield (%): --

Financials

  AKTX.OQ Industry Sector
P/E (TTM): -- 214.97 33.20
EPS (TTM): -2.62 -- --
ROI: -120.23 -3.79 13.23
ROE: -120.46 -5.32 15.28

BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics

* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING

May 11 2018

BRIEF-Akari Therapeutics Qtrly Loss Per Common Share $0.01

* AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

Mar 21 2018

Earnings vs. Estimates